Skip to content

亨斯曼

US · HUN #2975 按市值排名 上市于 1970
8.58 +0.02 +0.23%
实时 - 追踪5344个代码 - 心跳于394秒前 · 2026-10-16 20:01

估值 各估值倍数与自身5年区间的对比

市净率 0.57 低于历史水平 第4百分位
5年平均 1.18 · 在Chemicals中排名第6/15
市盈率 -8.35 低于历史水平 第28百分位
5年平均 -0.63 · 前瞻 -101.91
市销率 0.26 低于历史水平 第3百分位
5年平均 0.58 · 前瞻 0.25 · 在Chemicals中排名第5/16

同业对比 Chemicals

公司 市值 市盈率(TTM) 市净率 股息率
亨斯曼 (HUN) 1.50B -8.17 0.56 5.98%
Dow Inc (DOW) 21.62B -16.36 1.36 4.68%
Celanese Corp (CE) 5.21B -4.45 1.25 0.25%
Methanex (MEOH) 5.03B 68.38 1.96 1.14%
Olin (OLN) 1.78B -9.05 1.04 5.11%
REX American Resources (REX) 1.38B 11.43 2.05 0.00%

StockVane 追踪范围内同行业的其他公司。

Morningstar

★★★★★ 合理价值11.54 经济护城河None 不确定性High

当前股价低于晨星合理价值估算34.5%。

合理价值

Huntsman Corp earns a 5-star quantitative star rating, illustrating our stance that this share class offers a compelling opportunity for investors. The stock currently trades at a 24% discount to our quantitative fair value estimate of $11.54 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The company's valuation metrics increase our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's book value yield of 184.9% sits in the top 20% compared with peers globally. The market price is low relative to the book (accounting) value of the company's equity, which contributes to our view that shares are undervalued.

The company's balance sheet is an additional encouraging factor. Leverage can enable a company to invest in growth, potentially boosting shareholder value more than equity financing alone. The firm's EBITDA/interest coverage ratio of 3.6, for example, lies in the bottom 30% globally. Although the firm's ability to cover interest payments with EBITDA is limited, shares could sharply rebound if economic circumstances change or recent investments reduce fears of default. This characteristic further promotes our favorable price/fair value ratio.

经济护城河

With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

作者:Quantitative Equity Report

报价时间 2026-10-16 20:01:13 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

亨斯曼 讨论区 0 条评论

发表评论